Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA42014-31, R01CA178397)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 7 August 2020
Revised: 13 August 2020
Accepted: 23 September 2020
First Online: 30 September 2020
Compliance with ethical standards
:
: MWD is an advisory board member of Blueprint, Takeda, Incyte, and Sangamo, is a consultant for Blueprint, Fusion Pharma, Medscape, Novartis, Sangamo and DisperSol, and receives research funding from Blueprint, Takeda, Novartis, Incyte, SPARC, Leukemia & Lymphoma Society, and Pfizer.
Free to read: This content has been made available to all.